GlassScriptPhysician profile
Christopher Steven Bailes
NPI 1578945010
$6,895.50
in general payments reported to CMS, 2019-2025
39 companies · $1,770 in 2025
The $1,770 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,014 · 2023: $2,394 · 2024: $1,718 · 2025: $1,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,881.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,041.76 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $913.69 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $604.26 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $574.32 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $479.76 | 2022-2025 | Breztri, Nexium, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $423.51 | 2022-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $370.48 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $309.16 | 2022-2024 | Verquvo, Belsomra, Gardasil 9 |
| Amgen INC. | $264.70 | 2022-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $248.73 | 2022-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $203.36 | 2022-2024 | |
| Radius Health, INC. | $192.85 | 2022-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.49 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $96.70 | 2023-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $93.14 | 2022-2025 | Gvoke Hypopen |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $81.37 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $76.54 | 2024-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Exact Sciences Corporation | $64.35 | 2023-2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $60.86 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $57.98 | 2022-2024 | Trintellix |
| Phathom Pharmaceuticals, INC. | $53.57 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $47.27 | 2022-2024 | |
| Sanofi Pasteur INC. | $44.95 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $38.52 | 2024-2025 | Eliquis |
| Inari Medical, INC. | $37.95 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Paratek Pharmaceuticals, INC. | $36.53 | 2023 | Nuzyra |
| Si-Bone, INC. | $34.50 | 2024 | |
| Sumitomo Pharma America, INC. | $32.48 | 2023 | Gemtesa |
| Boston Scientific Corporation | $28.96 | 2025 | Bodyguardian |
| Averitas Pharma INC. | $23.84 | 2023 | Qutenza |
| Cequr Corporation | $23.01 | 2023 | Cequr Simplicity |
| Corium, LLC | $21.48 | 2023 | Adlarity |
| Biohaven Pharmaceutical Holding Company LTD. | $21.21 | 2022 | |
| Abbott Laboratories | $18.89 | 2024 | Octrode |
| Daiichi Sankyo INC. | $18.68 | 2024 | Injectafer |
| Nevro Corp. | $17.47 | 2023 | Senza |
| Seqirus USA INC | $17.26 | 2024 | Fluad, Flucelvax |
| Sunovion Pharmaceuticals INC. | $16.78 | 2022 | |
| Antares Pharma, INC. | $15.14 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bailes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.